89bio to participate in the h.c. wainwright 23rd annual global investment conference

San francisco, sept. 08, 2021 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that company's management will participate in the h.c. wainwright 23rd annual global investment conference to be held september 13-15, 2021.
ETNB Ratings Summary
ETNB Quant Ranking